Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.

about

Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.

Item

http://www.wikidata.org/entity/Q47098861

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@en

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@nl

type

Item

label

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@en

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@nl

prefLabel

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@en

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@nl

P1476

Brentuximab vedotin exerts pro ...... e germ cell tumour cell lines.

@en

P2093

Anna Casati

http://www.w3.org/2001/XMLSchema#string

Barbara Götz

http://www.w3.org/2001/XMLSchema#string

Cornelius van Beekum

http://www.w3.org/2001/XMLSchema#string

Dagmar Dilloo

http://www.w3.org/2001/XMLSchema#string

Dominik T Schneider

http://www.w3.org/2001/XMLSchema#string

Gabriele Calaminus

http://www.w3.org/2001/XMLSchema#string

Hubert Schorle

http://www.w3.org/2001/XMLSchema#string

Rogerio B Craveiro

http://www.w3.org/2001/XMLSchema#string

P2860

Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

Expression of cathepsin P mRNA, protein and activity in the rat choriocarcinoma cell line, Rcho-1, during giant cell transformation

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.

The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Management of germ cell tumors in children: approaches to cure.

P304

568-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.13344

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Nettersheim

Stefan Schönberger

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28941150

http://www.w3.org/2001/XMLSchema#string

P932

5742680

http://www.w3.org/2001/XMLSchema#string